此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2026年11月12日 更新者:Qingqing Cai、Sun Yat-sen University

A Prospective, Multicenter, Phase II Clinical Study of Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

研究概览

研究类型

介入性

注册 (估计的)

29

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510000
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • 接触:
          • Ning Su
      • Guangzhou、Guangdong、中国、510000
        • Sun Yat-sen Univercity Cancer Center, Sun Yat-sen University
        • 接触:
      • Guangzhou、Guangdong、中国、510000
        • The Fifth Affiliated Hospital of Guangzhou Medical University
        • 接触:
          • Runhui Zheng

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Willing to participate in the clinical study and signed informed consent.
  2. Age ≥18 years, no gender restrictions.
  3. Histologically confirmed relapsed or refractory diffuse large B-cell lymphoma; ineligible for or unable to access autologous stem cell transplantation (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy.
  4. Has at least one measurable or assessable lesion.
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤
  6. Adequate major organ function.

Exclusion Criteria:

  1. DLBCL with central nervous system involvement or Burkitt lymphoma.
  2. Disease progression following prior frontline treatment with a Bruton tyrosine kinase inhibitor (BTKi).
  3. Active human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection.
  4. Inability to swallow capsules or significant gastrointestinal impairment that may affect drug absorption.
  5. Other progressive malignancy requiring active treatment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Tafasitamab in combination with Lenalidomide, Rituximab and Orelabrutinib

Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.

12mg/kg, IV, C1-3: D1, 8, 15, 22 (with an additional loading dose on C1D4), C4-12: D1, 15.

25mg, PO, day 1-21 of cycle 1-12

375mg/m2, IV, day 1 of cycle 1-4

150mg or 100mg, PO, day 1-28 of cycle 1-4

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete response rate (CRR)
大体时间:Up to 12 cycles ( each cycle is 28 days)

CRR was defined as the proportion of patients who achieve complete response (CR)

Up to 12 cycles ( each cycle is 28 days)

次要结果测量

结果测量
措施说明
大体时间
Objective response rate (ORR)
大体时间:Up to 12 cycles (each cycle is 28 days)

ORR was defined as the proportion of patients who achieve complete response (CR) or partial response (PR)

Up to 12 cycles (each cycle is 28 days)
Disease control rate (DCR)
大体时间:Up to 12 cycles (each cycle is 28 days)

DCR was defined as the proportion of patients who achieve complete response (CR), partial response (PR) and stable disease (SD)

Up to 12 cycles (each cycle is 28 days)
Duration of Response (DoR)
大体时间:up to 3 years

DoR was defined as the time from the patients's first efficacy assessment achieving CR or PR until disease progression

up to 3 years
Duration of Complete Response (DoCR)
大体时间:up to 3 years

DoCR was defined as the time from the patients's first efficacy assessment achieving CR until disease progression

up to 3 years
Progression-free survival (PFS)
大体时间:up to 3 years

PFS was defined as the time from the date of the first administration of any study drug to the date of tumor progression or death from any cause

up to 3 years
Overall survival (OS)
大体时间:up to 3 years

OS was defined as the time from the date of the first administration of any study drug until death from any cause

up to 3 years
Time to Response (TTR)
大体时间:Up to 12 cycles (each cycle is 28 days)

TTR was defined as the time from the initiation of treatment to the patients's first efficacy assessment achieving CR or PR

Up to 12 cycles (each cycle is 28 days)
Adverse events
大体时间:Up to 28 days after the last dose of study drug

The incidence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

Up to 28 days after the last dose of study drug
Change in Quality of Life
大体时间:Up to 3 years

Quality of life will be assessed using the EORTC QLQ-C30 questionnaire

Up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2026年11月8日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅